Hedge Fund Investors

Perceptive Advisors

Perceptive Advisors is a hedge fund that has invested in tech-sector companies.

Venture Investor Overview

Venture Investor
Perceptive Advisors
Status
Active
Investor Type
Hedge Fund
Activity Level
139 transactions
Funds Raised
At least $210 million
Industry Focus
Biopharmaceutical
Consumer
Enterprise IT
Healthcare IT
Healthcare Services
Medical Devices & Instruments

Contact Information

Contact
Joseph Edelman
Title
Chief Executive Officer
Mailing Address
51 Astor Pl. 10th Floor
New York, NY 10003
USA
Phone
(646) 205-5300
Website
www.perceptivelife.com
Email Address
[email protected]

Background Information

Overview
Perceptive Advisors LLC is an employee owned hedge fund sponsor. The firm primarily provides its services to pooled investment vehicles. It invests in public equity markets of the United States. The firm employs hedging strategy using long and short equity positions, equity options, and index options. It also employs technical analysis to make its investments. The firm conducts in-house research to make its investments. It typically invests in healthcare companies in biotechnology. Perceptive Advisors LLC was founded in 1999 and is based in New York City.
Profile
Perceptive Advisors LinkedIn Company Profile
Social Media
Perceptive Advisors Company Twitter Account
Company News
Perceptive Advisors News
Facebook
Perceptive Advisors on Facebook
YouTube
Perceptive Advisors on YouTube
Last Transaction
4/24/2024

Transaction History

Our records indicate that Perceptive Advisors invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Company
Date
Amount
Endeavor BioMedicines
4/24/2024
$132,500,000
TORL BioTherapeutics
4/10/2024
$158,000,000
Neurosterix
4/4/2024
$63,000,000
Capstan Therapeutics
3/21/2024
$175,000,000
Sionna Therapeutics
3/7/2024
$182,000,000
Mainstay Medical
2/27/2024
$125,000,000
Freenome
2/15/2024
$254,000,000
Beta Bionics
9/1/2023
$100,000,000
Rapport Therapeutics
8/23/2023
$150,000,000
AsclepiX Therapeutics
7/26/2023
$10,000,000
A-Alpha Bio
7/25/2023
$22,400,000
OnKure
5/23/2023
$54,000,000
Kindbody
3/2/2023
$100,000,000
CARGO Therapeutics
3/1/2023
$200,000,000
Peroxitech Therapeutics
12/13/2022
$25,000,000
Zenas BioPharma
11/8/2022
$118,000,000
InSightec
9/1/2022
$200,000,000
Cerebral Therapeutics
6/28/2022
$40,000,000
Neuron23
3/30/2022
$100,000,000
DNAnexus
3/8/2022
$200,000,000
Omada Health
3/7/2022
$192,000,000
Synthego
3/1/2022
$200,000,000
Ceptur Therapeutics
1/28/2022
$75,000,000
Avenge Bio
1/11/2022
$45,000,000
Mythic Therapeutics
12/17/2021
$103,000,000
A-Alpha Bio
9/9/2021
$20,000,000
HilleVax
9/9/2021
$135,000,000
Emulate
9/8/2021
$82,000,000
Genome Medical
8/31/2021
$60,000,000
Bridge to Life
8/25/2021
$56,000,000
Amylyx Pharmaceuticals
7/21/2021
$135,000,000
Kindbody
6/28/2021
$62,000,000
RayzeBio
6/16/2021
$108,000,000
Cue Health
5/14/2021
$325,000,000
Juno Diagnostics
5/13/2021
$25,000,000
Affinia Therapeutics
5/4/2021
$110,000,000
Forge Biologics
4/30/2021
$120,000,000
Pyxis Oncology
3/31/2021
$152,000,000
Crossover Health
3/30/2021
$168,000,000
Graphite Bio
3/16/2021
$150,000,000
Pipeline Therapeutics
2/12/2021
$80,000,000
Day One Biopharmaceuticals
2/11/2021
$130,000,000
Mivi Neuroscience
1/22/2021
$35,000,000
Impulse Dynamics
1/13/2021
$60,000,000
Earli
1/13/2021
$40,000,000
IsoPlexis
1/11/2021
$135,000,000
Affinivax
1/11/2021
$226,000,000
Immuneering
1/6/2021
$62,000,000
Neuron23
12/17/2020
$113,500,000
Adagio Medical
11/17/2020
$42,500,000
Prometheus Biosciences
11/10/2020
$130,000,000
AavantiBio
10/23/2020
$107,000,000
Willow Pump
9/23/2020
$55,000,000
Escient Pharmaceuticals
9/15/2020
$77,500,000
Zymergen
9/10/2020
$300,000,000
Rain Therapeutics
9/9/2020
$63,000,000
Freenome
8/31/2020
$270,000,000
Kronos Bio
8/26/2020
$155,000,000
ReViral
8/26/2020
$44,000,000
Taysha Gene Therapies
8/7/2020
$95,000,000
Thrive Earlier Detection
7/30/2020
$257,000,000
Forge Biologics
7/23/2020
$40,000,000
Unum Therapeutics
7/10/2020
$104,400,000
Kindbody
7/10/2020
$32,000,000
Pear Therapeutics
7/8/2020
$50,000,000
Genome Medical
7/2/2020
$14,000,000
AsclepiX Therapeutics
6/25/2020
$35,000,000
4D Molecular Therapeutics
6/17/2020
$75,000,000
C4 Therapeutics
6/17/2020
$170,000,000
CereVasc
6/10/2020
$44,000,000
DNAnexus
6/10/2020
$100,000,000
Athira Pharma
6/5/2020
$85,000,000
Nautilus Biotechnology
5/22/2020
$76,000,000
Atea Pharmaceuticals
5/21/2020
$215,000,000
Zucara Therapeutics
4/3/2020
$21,000,000
Outset Medical
2/6/2020
$125,000,000
Cerebral Therapeutics
1/9/2020
$35,000,000
Sonendo
1/8/2020
$85,000,000
ArcherDX
12/19/2019
$55,000,000
Quellis Biosciences
12/11/2019
$17,000,000
Zentalis Pharmaceuticals
12/11/2019
$85,000,000
Black Diamond Therapeutics
12/6/2019
$85,000,000
Avidity Biosciences
11/14/2019
$100,000,000
Nuvation Bio
10/30/2019
$275,000,000
Oncorus
8/22/2019
$79,500,000
Landos Biopharma
8/14/2019
$60,000,000
Freenome
7/25/2019
$160,000,000
Frequency Therapeutics
7/24/2019
$62,000,000
Orchestra BioMed
7/16/2019
$34,000,000
PanTheryx
6/27/2019
$50,000,000
Genome Medical
6/12/2019
$23,000,000
ArcherDX
5/16/2019
$60,000,000
Poseida Therapeutics
4/23/2019
$142,000,000
Kindbody
4/18/2019
$15,000,000
Fusion Pharmaceuticals
4/3/2019
$105,000,000
SpringWorks Therapeutics
4/2/2019
$125,000,000
Saama
3/28/2019
$40,000,000
Saama
3/26/2019
$40,000,000
BridgeBio Pharma
1/24/2019
$299,200,000
Black Diamond Therapeutics
1/11/2019
$85,000,000
Relay Therapeutics
12/21/2018
$400,000,000
Stoke Therapeutics
10/24/2018
$90,000,000
Lyra Therapeutics
9/27/2018
$29,500,000
Renovia
9/25/2018
$42,300,000
Allogene Therapeutics
9/10/2018
$120,000,000
4D Molecular Therapeutics
9/6/2018
$90,000,000
Outset Medical
8/29/2018
$132,000,000
Orchard Therapeutics
8/14/2018
$150,000,000
Alector
7/26/2018
$133,000,000
Rain Therapeutics
5/22/2018
$18,400,000
Eidos Therapeutics
4/6/2018
$64,000,000
IDEAYA Biosciences
3/16/2018
$94,000,000
Crinetics Pharmaceuticals
3/15/2018
$63,500,000
PROCEPT BioRobotics
2/22/2018
$118,000,000
Partner Therapeutics
2/2/2018
$60,000,000
Vitruvias Therapeutics
1/6/2018
$11,500,000
AEGEA
1/3/2018
$40,000,000
Counsyl
11/7/2017
$80,000,000
Landos Biopharma
9/22/2017
$10,000,000
BridgeBio Pharma
9/14/2017
$135,000,000
Xontogeny
5/19/2017
$25,000,000
Outset Medical
5/4/2017
$76,500,000
Solid Biosciences
3/31/2017
$50,000,000
Motus GI
3/3/2017
$30,000,000
True North Therapeutics
10/19/2016
$45,000,000
Vyome Biosciences
8/24/2016
$14,000,000
Zymeworks
1/8/2016
$61,500,000
True North Therapeutics
12/3/2015
$40,000,000
Clearside Biomedical
12/3/2015
$20,000,000
Solid GT
11/5/2015
$42,500,000
Oncobiologics
7/27/2015
$31,000,000
CytomX Therapeutics
6/17/2015
$70,000,000
REGENXBIO
5/20/2015
$70,500,000
MyoKardia
4/30/2015
$46,000,000
Global Blood Therapeutics
1/6/2015
$48,000,000
Blueprint Medicines
11/14/2014
$50,000,000
Invitae
10/13/2014
$120,000,000
Bellicum Pharmaceuticals
8/27/2014
$55,000,000
Virobay
7/17/2014
$8,000,000

 

Investor Contacts

Title
Name
Email & Social
Managing Director
Michael Altman
  Michael Altman LinkedIn Profile  Michael Altman Twitter Account  Michael Altman News  Michael Altman on Facebook
Chief Executive Officer
Joseph Edelman
  Joseph Edelman LinkedIn Profile  Joseph Edelman Twitter Account  Joseph Edelman News  Joseph Edelman on Facebook
Managing Director
Hossein Ekrami
  Hossein Ekrami LinkedIn Profile  Hossein Ekrami Twitter Account  Hossein Ekrami News  Hossein Ekrami on Facebook
Managing Director
Ellen Hukkelhoven
  Ellen Hukkelhoven LinkedIn Profile  Ellen Hukkelhoven Twitter Account  Ellen Hukkelhoven News  Ellen Hukkelhoven on Facebook
Investment Director
Adam Stone
  Adam Stone LinkedIn Profile  Adam Stone Twitter Account  Adam Stone News  Adam Stone on Facebook
Managing Director
Craig Yeshion
  Craig Yeshion LinkedIn Profile  Craig Yeshion Twitter Account  Craig Yeshion News  Craig Yeshion on Facebook

 

Funds

Our database includes the following fund closing(s) for Perceptive Advisors. If we are missing funds, please contact us.

Fund Description
Vintage Date
Fund Amount
Perceptive Xontogeny Venture Fund
12/10/2019
$210,000,000

 

Portfolio Companies

Perceptive Advisors has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Tech Company
4D Molecular Therapeutics
A-Alpha Bio
AavantiBio
Adagio Medical
AEGEA
Affinia Therapeutics
Affinivax
Alector
Allogene Therapeutics
Amylyx Pharmaceuticals
ArcherDX
AsclepiX Therapeutics
Atea Pharmaceuticals
Athira Pharma
Avenge Bio
Avidity Biosciences
Bellicum Pharmaceuticals
Beta Bionics
Black Diamond Therapeutics
Blueprint Medicines
Bridge to Life
BridgeBio Pharma
C4 Therapeutics
Capstan Therapeutics
CARGO Therapeutics
Ceptur Therapeutics
Cerebral Therapeutics
CereVasc
Clearside Biomedical
Counsyl
Crinetics Pharmaceuticals
Crossover Health
Cue Health
CytomX Therapeutics
Day One Biopharmaceuticals
DNAnexus
Earli
Eidos Therapeutics
Emulate
Endeavor BioMedicines
Escient Pharmaceuticals
Forge Biologics
Freenome
Frequency Therapeutics
Fusion Pharmaceuticals
Genome Medical
Global Blood Therapeutics
Graphite Bio
HilleVax
IDEAYA Biosciences
Immuneering
Impulse Dynamics
InSightec
Invitae
IsoPlexis
Juno Diagnostics
Kindbody
Kronos Bio
Landos Biopharma
Lyra Therapeutics
Mainstay Medical
Mivi Neuroscience
Motus GI
MyoKardia
Mythic Therapeutics
Nautilus Biotechnology
Neuron23
Neurosterix
Nuvation Bio
Omada Health
Oncobiologics
Oncorus
OnKure
Orchard Therapeutics
Orchestra BioMed
Outset Medical
PanTheryx
Partner Therapeutics
Pear Therapeutics
Peroxitech Therapeutics
Pipeline Therapeutics
Poseida Therapeutics
PROCEPT BioRobotics
Prometheus Biosciences
Pyxis Oncology
Quellis Biosciences
Rain Therapeutics
Rapport Therapeutics
RayzeBio
REGENXBIO
Relay Therapeutics
Renovia
ReViral
Saama
Sionna Therapeutics
Solid Biosciences
Solid GT
Sonendo
SpringWorks Therapeutics
Stoke Therapeutics
Synthego
Taysha Gene Therapies
Thrive Earlier Detection
TORL BioTherapeutics
True North Therapeutics
Unum Therapeutics
Virobay
Vitruvias Therapeutics
Vyome Biosciences
Willow Pump
Xontogeny
Zenas BioPharma
Zentalis Pharmaceuticals
Zucara Therapeutics
Zymergen
Zymeworks

 

 

 

 

Browse more hedge fund investors:

Partners Fund | Phase 2 Partners

 

Share this article

 

About Our Hedge Fund Database

Our hedge fund transaction data comes from VentureDeal.com, a leading provider of tech company funding transaction data.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.